LYKALABSNSELyka Labs Limited· PharmaceuticalsMediumNeutral
Announced Thu, 30 Apr · 17:08 IST

Lyka Labs Limited has informed the Exchange about Credit Rating

Debt PrepaidCredit & Debt View source PDF

LYKALABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-3.7%1-day move
₹59.70
prior close
₹59.75
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.8+0.4+0.4-4.3-3.7-0.3+4.5+9.5+7.2+5.2+3.9+1.1+21.8
Up moveDown movePending
AI summary

India Ratings & Research Pvt. Ltd. has affirmed the rating of Lyka Labs' bank loan facilities at IND BBB+/Stable/IND A2. The size of the bank facilities was reduced from INR 363.1 million to INR 332.8 million. The rating action was 'Affirmed', meaning there was no change in the credit rating or outlook. The BBB+ rating is an investment-grade rating indicating moderate safety for debt repayment. The reduction in facility size from INR 363.1 million to INR 332.8 million suggests partial debt repayment or prepayment.

Likely market impact

The affirmed investment-grade rating is positive for shareholders as it indicates the company's ability to service its debt obligations remains stable. The reduction in bank facility size suggests the company has prepaid debt, which could strengthen its balance sheet.